Synergy Pharmaceuticals Offers Update On Ongoing Irritable Bowel Syndrome With Constipation Program

By: via Benzinga
Synergy Pharmaceuticals Inc (NYSE: SGYP) revealed that it reached the FDA mid-cycle review milestone for the plecanatide new drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.